Efficacy News and Research

RSS

Data undermining Thai HIV vaccine trial not reported, AHF disappointed

AIDS Healthcare Foundation (AHF), the largest non-profit HIV/AIDS healthcare provider in the US which now provides treatment and services for more than 110,000 individuals in 21 countries worldwide in the US, Africa, Latin America/Caribbean and Asia, expressed frustration and disappointment at the news that data that seriously undermines a widely reported Thai HIV vaccine trial were not released publicly when other, more favorable data from the vaccine trial were publicly reported late last month.

12 Oct 2009

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Fibrocell Science, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults.

12 Oct 2009

Socioeconomic and geographic disparities in the use of breast-conservating therapy

According to a new study published in the October issue of the Journal of the American College of Surgeons, although breast-conserving surgery (BCS), commonly known as lumpectomy, is increasingly being used to treat older women with nonmetastatic invasive breast cancer, there are still significant socioeconomic and geographic disparities in the use of this type of therapy.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

Number of doses, delivery system and setting impact radiation price tag

When cancer spreads to the bone, radiation treatments can help relieve the pain caused by the tumor. But how best to deliver the radiation may vary widely from one oncologist to the next.

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Berkshire Partners makes $125 million growth equity investment to support United BioSource

United BioSource Corporation today announced that Berkshire Partners LLC, a Boston-based private equity firm, has made a $125 million growth equity investment to support the Company’s evidence-based acquisition and service offering expansion strategy.

9 Oct 2009

Research study on HPV vaccination efficacy for boys and girls

Persistent infection with high-risk types of human papillomavirus (HPV), a sexually transmitted virus, is known to be a cause of cervical cancer. Current guidelines prioritize HPV vaccination of pre-adolescent girls, which has been shown to be cost-effective in previous studies, but the value of vaccinating boys in the United States has been unclear.

9 Oct 2009

Refurbished pacemakers: No complications for patients

Patients who received refurbished pacemakers donated from Detroit area funeral homes survived without complications from the devices, according to a case series reported by the University of Michigan Cardiovascular Center.

9 Oct 2009

CardioPharma to submit an NDA for CardiaPill

CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO.

9 Oct 2009

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Lpath, Inc., the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP™ in wet-AMD patients.

8 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

CombinatoRx' Prednisolone/Dipyridamole Combination abstract to be presented at the ACR 2009

CombinatoRx, Incorporated today announced that its abstract entitled, “CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results”, has been accepted for oral presentation at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia on October 20, 2009.

8 Oct 2009

Clinical and health status outcomes information repository of heart attack patients completed

An important observational registry evaluating processes of care and one-year outcomes of over 4300 heart attack patients is now being completed. Researchers at the Saint Luke's Mid America Heart Institute in Kansas City, MO have led this observational research study in collaboration with 23 other hospitals throughout the U.S.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced that they have received a notice of allowance from the U.S. Patent and Trademark Office for its first U.S. patent application.

8 Oct 2009

Efficacy News and Research

Data undermining Thai HIV vaccine trial not reported, AHF disappointed

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Socioeconomic and geographic disparities in the use of breast-conservating therapy

Presentations on efficacy of interferon to combat influenza

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Number of doses, delivery system and setting impact radiation price tag

New soy germ-based ingredient improves menopausal symptoms

Berkshire Partners makes $125 million growth equity investment to support United BioSource

Research study on HPV vaccination efficacy for boys and girls

Refurbished pacemakers: No complications for patients

CardioPharma to submit an NDA for CardiaPill

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

CombinatoRx' Prednisolone/Dipyridamole Combination abstract to be presented at the ACR 2009

Clinical and health status outcomes information repository of heart attack patients completed

Mimetogen Pharmaceuticals completes its equity financing

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News